Brain Cancer | Specialty

The brain cancer condition center is a comprehensive resource for clinical news and expert insights on brain cancer. Read more at OncLive.

FDA Grants Fast Track Designation to RAD101 for Imaging of Brain Metastases

June 12th 2025

The FDA granted fast track designation to RAD101 for imaging of cerebral metastases from various solid tumors, including leptomeningeal metastases.

Iopofosine I-131 Demonstrates Safety and Early Efficacy in Pediatric R/R High-Grade Glioma

June 11th 2025

Data from the phase 1 CLOVER-2 trial demonstrated the safety and activity of iopofosine I-131 in relapsed/refractory pediatric high-grade glioma.

Revisit Every OncLive On Air Episode From May 2025

May 30th 2025

Read a recap of the episodes of OncLive On Air that debuted in May 2025.

Dr Merrell on Current Treatment Modalities for Gliomas

May 28th 2025

Ryan T. Merrell, MD, discusses current treatment modalities for gliomas in recognition of Brain Tumor Awareness Month.

Awareness Efforts Aim to Improve Early Recognition and Multidisciplinary Care for Brain Tumors

May 28th 2025

Ryan Merrell, MD, underscores the need for early glioma detection, advances in IDH-targeted therapy, and emerging immunotherapy in glioblastoma care.

Mirdametinib Earns Positive CHMP Opinion for NF1-Associated Plexiform Neurofibromas

May 23rd 2025

The EMA’s CHMP has issued a positive opinion for mirdametinib for pediatric and adult patients with NF1-associated plexiform neurofibromas.

Cortice Biosciences Transfers Orphan Drug Designations for TPI 287 in Brain Cancer and CNS Diseases

May 21st 2025

CNS Pharmaceuticals has acquired the orphan drug designations for TPI 287 in gliomas, pediatric neuroblastoma, and progressive supranuclear palsy.

FDA Awards RMAT Designation to BCB-276 CAR T-Cell Therapy for Diffuse Intrinsic Pontine Glioma

May 19th 2025

The B7-H3–directed CAR T-cell therapy BCB-276 received RMAT designation for the treatment of patients with diffuse intrinsic pontine glioma.

Rhenium (Re186) Obisbemeda Shows Initial Safety, Clinical Benefit in Leptomeningeal Metastases

May 14th 2025

The novel injectable radiotherapy 186RNL showed safety and clinical activity as treatment for patients with leptomeningeal metastases.

Roswell Park Announces Positive Progress in Clinical Trial of Novel Immunotherapy SurVaxM

May 12th 2025

The ongoing phase 2B SURVIVE clinical trial of SurVaxM in glioblastoma will continue following an interim analysis of trial data.

Updated NCCN Guidelines Recommend Naxitamab in High-Risk Neuroblastoma

May 7th 2025

The NCCN guidelines now recommend a naxitamab-based regimen for high-risk neuroblastoma.

The OncFive: Top Oncology Articles for the Week of 4/27

May 3rd 2025

The FDA issues a CRL to a glioma imaging agent, an sBLA seeking approval of an epcoritamab triplet in follicular lymphoma is planned for submission, and more.

FDA Issues CRL to TLX101-CDx for Glioma Imaging

May 1st 2025

The FDA issued a complete response letter to the new drug application seeking the approval of TLX101-CDx as an imaging agent for glioma.

BCB-276 Earns FDA Breakthrough Therapy Nod for Pediatric Diffuse Intrinsic Pontine Glioma

April 23rd 2025

The FDA granted breakthrough therapy designation to BCB-276 for pediatric diffuse intrinsic pontine glioma.

TLX101 Has Preliminary Safety and Clinical Activity in Recurrent High-Grade Glioma

April 16th 2025

TLX101 was associated with a favorable safety profile and preliminary signs of clinical activity in patients with recurrent high-grade glioma.

FDA Greenlights Bevacizumab Biosimilar in Multiple Solid Tumor Indications

April 10th 2025

The bevacizumab biosimilar Jobevne was approved by the FDA for the treatment of several solid tumor types, including mCRC, NSCLC, and RCC.

FDA Clears ZEISS INTRABEAM 700 for Intraoperative Radiation Therapy in Neuro-Oncology & Breast Cancer

April 9th 2025

The ZEISS INTRABEM 700 platform received 510(k) clearance from the FDA for use in neuro-oncology and breast cancer surgery.

Dr Kelly on Early Efficacy Signals and Safety With Sacituzumab Govitecan in Recurrent Glioblastoma

April 7th 2025

William Kelly, MD, discusses the safety and efficacy signals seen with sacituzumab govitecan in a phase 2 study of patients with recurrent glioblastoma.

VXM01 Plus Avelumab Is Safe and Shows Preliminary Clinical Activity in Recurrent Glioblastoma

April 7th 2025

The combination of VXM01 and avelumab was well tolerated and has the potential to generate clinically meaningful responses in recurrent glioblastoma.

FDA Gives RPDD to NEO100 for Pediatric-Type Diffuse High-Grade Glioma

April 3rd 2025

NEO100 was given rare pediatric disease designation by the FDA for the treatment of patients with pediatric-type diffuse high-grade glioma.